Scott Tagawa, MD, MS, FACP
Scott Tagawa, MD, MS, FACP, currently serves as Professor of Medicine and Urology at Weill Cornell Medicine, and is an Attending Physician at New York-Presbyterian – Weill Cornell Medical Center. Dr. Tagawa also serves as leader of the GU Disease Management Team and co-leader of the Experimental Therapeutics Program of the Meyer Cancer Center at Weill Cornell Medicine. He leads clinical trials in the areas of prostate, kidney, and bladder cancer, and specializes in drug development and theranostics in prostate cancer.
Articles by Scott Tagawa, MD, MS, FACP
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
Scott Tagawa, MD, MS, FACP, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients.
Scott Tagawa, MD, MS, FACP, explains the distinct ways in which PSMA imaging compares to standard cross-sectional imaging.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.